Literature DB >> 17662390

Acute Myocardial Infarction with Hyperoxemic Therapy (AMIHOT): a prospective, randomized trial of intracoronary hyperoxemic reperfusion after percutaneous coronary intervention.

William W O'Neill1, Jack L Martin, Simon R Dixon, Antonio L Bartorelli, Daniela Trabattoni, Pranobe V Oemrawsingh, Douwe E Atsma, Michael Chang, William Marquardt, Jae K Oh, Mitchell W Krucoff, Raymond J Gibbons, J Richard Spears.   

Abstract

OBJECTIVES: This study sought to determine whether hyperoxemic reperfusion with aqueous oxygen (AO) improves recovery of ventricular function after percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI).
BACKGROUND: Hyperbaric oxygen reduces myocardial injury and improves ventricular function when administered during ischemia-reperfusion.
METHODS: In a prospective, multicenter study, 269 patients with acute anterior or large inferior AMI undergoing primary or rescue PCI (<24 h from symptom onset) were randomly assigned after successful PCI to receive hyperoxemic reperfusion (treatment group) or normoxemic blood autoreperfusion (control group). Hyperoxemic reperfusion was performed for 90 min using intracoronary AO. The primary end points were final infarct size at 14 days, ST-segment resolution, and delta regional wall motion score index of the infarct zone at 3 months.
RESULTS: At 30 days, the incidence of major adverse cardiac events was similar between the control and AO groups (5.2% vs. 6.7%, p = 0.62). There was no significant difference in the incidence of the primary end points between the study groups. In post-hoc analysis, anterior AMI patients reperfused <6 h who were treated with AO had a greater improvement in regional wall motion (delta wall motion score index = 0.54 in control group vs. 0.75 in AO group, p = 0.03), smaller infarct size (23% of left ventricle in control group vs. 9% of left ventricle in AO group, p = 0.04), and improved ST-segment resolution compared with normoxemic controls.
CONCLUSIONS: Intracoronary hyperoxemic reperfusion was safe and well tolerated after PCI for AMI, but did not improve regional wall motion, ST-segment resolution, or final infarct size. A possible treatment effect was observed in anterior AMI patients reperfused <6 h of symptom onset.

Entities:  

Mesh:

Year:  2007        PMID: 17662390     DOI: 10.1016/j.jacc.2007.01.099

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  16 in total

Review 1.  Advances in emerging nondrug therapies for acute stroke 2007.

Authors:  Aneesh B Singhal; Eng H Lo
Journal:  Stroke       Date:  2008-01-10       Impact factor: 7.914

Review 2.  Reactive oxygen species in cardiovascular disease.

Authors:  Koichi Sugamura; John F Keaney
Journal:  Free Radic Biol Med       Date:  2011-05-15       Impact factor: 7.376

Review 3.  Oxygen therapy for acute myocardial infarction.

Authors:  Juan B Cabello; Amanda Burls; José I Emparanza; Susan E Bayliss; Tom Quinn
Journal:  Cochrane Database Syst Rev       Date:  2016-12-19

Review 4.  Controlling Reperfusion Injury With Controlled Reperfusion: Historical Perspectives and New Paradigms.

Authors:  Demetria M Fischesser; Bin Bo; Rachel P Benton; Haili Su; Newsha Jahanpanah; Kevin J Haworth
Journal:  J Cardiovasc Pharmacol Ther       Date:  2021-09-17       Impact factor: 2.457

Review 5.  Myocardial ischemia-reperfusion injury: a neglected therapeutic target.

Authors:  Derek J Hausenloy; Derek M Yellon
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

6.  Hyperoxemic reperfusion after prolonged cardiac arrest in a rat cardiopulmonary bypass resuscitation model.

Authors:  Steve T Yeh; Sverre E Aune; Traci A Wilgus; Allison E Parent; Mark G Angelos
Journal:  Resuscitation       Date:  2012-09-14       Impact factor: 5.262

7.  Conditioning the heart to prevent myocardial reperfusion injury during PPCI.

Authors:  Derek J Hausenloy
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2012-04

8.  An Injectable Oxygen Release System to Augment Cell Survival and Promote Cardiac Repair Following Myocardial Infarction.

Authors:  Zhaobo Fan; Zhaobin Xu; Hong Niu; Ning Gao; Ya Guan; Chao Li; Yu Dang; Xiaoyu Cui; Xuanyou Liu Liu; Yunyan Duan; Haichang Li; Xinyu Zhou; Pei-Hui Lin; Jianjie Ma; Jianjun Guan
Journal:  Sci Rep       Date:  2018-01-22       Impact factor: 4.379

9.  lncRNA expression character associated with ischemic reperfusion injury.

Authors:  Xiaowei Wu; Hongyi Zhu; Suhua Zhu; Maojuan Hao; Qingping Li
Journal:  Mol Med Rep       Date:  2017-07-21       Impact factor: 2.952

Review 10.  Novel cardioprotective and regenerative therapies in acute myocardial infarction: a review of recent and ongoing clinical trials.

Authors:  Nicholas B Spath; Nicholas L Mills; Nicholas L Cruden
Journal:  Future Cardiol       Date:  2016-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.